SCHEMBL8302237

SCHEMBL8302237

CCC(C)c1cc(O)no1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.36
RXRA P19793 1/20 0.36
ALDH1A1 P00352 2/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RORC P51449 1/20 0.34
HDAC4 P56524 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
RAB9A P51151 2/20 0.31
NPC1 O15118 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20799347 0.82
SCHEMBL24443098 0.82 NPC1 (0.30) RAB9ANPC1
SCHEMBL24743767 0.79
SCHEMBL24796605 0.78 GPR84 (0.48)
SCHEMBL25042525 0.77 POLB (0.32) ALDH1A1HPGD
SCHEMBL16851608 0.77
SCHEMBL16851546 0.77
SCHEMBL16851631 0.77
SCHEMBL16851570 0.77
SCHEMBL16851639 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230008367-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES ABIONYX PHARMA SA (FR) 2023-01-12 US disclosed
US-20220363632-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2022-11-17 US disclosed
US-11084773-B1 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2021-08-10 US disclosed
US-8338637-B2 Glaucoma; prostaglandin receptor modulators; cyclopentyl compounds such as 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid ALLERGAN, INC. (US) 2012-12-25 US disclosed
US-7897629-B2 Therapeutic compounds ALLERGAN, INC. (US) 2011-03-01 US disclosed
US-7732464-B2 Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2010-06-08 US disclosed
US-20090247594-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-10-01 US disclosed
US-20080300269-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2008-12-04 US disclosed
WO-2005003124-A1 HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300269-A1 THERAPEUTIC COMPOUNDS THPO, HLA-C, PIGO TSHR 3352/4885RXRA 1395/4885ALDH1A1 1004/4885
US-20090247594-A1 THERAPEUTIC COMPOUNDS ACER2, SLC10A1, ASAH2 TSHR 3467/4885RXRA 348/4885ALDH1A1 374/4885
US-11084773-B1 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease CPT1A, PPARG, PC TSHR 2668/4885RXRA 319/4885ALDH1A1 283/4885
US-20230008367-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES SLC10A1, CPT1A, CES1 TSHR 3466/4885RXRA 895/4885ALDH1A1 176/4885
US-20220363632-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A TSHR 3875/4885RXRA 872/4885ALDH1A1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.